|
James Niedel is a Managing Director and focuses on our
biopharmaceuticals efforts. He joined the venture industry
in 2002 and was one of the founders of New Leaf in 2005.
Prior to those activities, Jim was Chief
Science and Technology Officer for GlaxoSmithKline and from
1995 to 2001 he was a member of the board of directors of Glaxo Wellcome plc with responsibility for Global Research
and Development, Information Technology and Product
Strategy. From 1988 to 1995, he was VP Research and SVP R&D
for the United States' subsidiary of Glaxo. Before joining the
pharmaceutical industry, Jim was Professor of Medicine and
Chief of the division of Clinical Pharmacology at Duke
Medical School, where he had completed an Internal Medicine
residency and a Hematology-Oncology fellowship. He received
M.D. and Ph.D. (Biochemistry) degrees from the
University of Miami, was selected a Searle Scholar, and is a
Fellow of the Royal College of Physicians (London).
Board Seats:
Intarcia Therapeutics,
Tioga Pharmaceuticals,
Tolerx
Contact Information:
jim@nlvpartners.com
(646) 871-6400
|
 |
